The ALPHABET study on breast cancer is enrolling patients
Enrollment of patients with HER2+ metastatic breast cancer and PIK3CA mutation has been started at IEO, to evaluate the addition of alpelisib to current therapies
Enrollment of patients with HER2+ metastatic breast cancer and PIK3CA mutation has been started at IEO, to evaluate the addition of alpelisib to current therapies